Protectus Medical Devices` CEO Dr. John Salstrom Releases Letter to Shareholders

Discussion Updates Shareholders; Speaks to Future Corporate Initiatives and
Expanding Opportunities for the Protectus Safety Syringe
MINNEAPOLIS--(Business Wire)--
Protectus Medical Devices, Inc. ("Protectus Medical Devices") (OTCBB: PTMD), a
developer and marketer of innovative medical devices, today released a letter to
shareholders from Dr. John Salstrom, President and Chief Executive Officer,
providing investors with management`s vision for the company in the remainder of
2009 and beyond.

Dear Shareholders:

As Chief Executive Officer of Protectus Medical Devices, it is my pleasure to
communicate with you today and provide you with a few details of our various
corporate initiatives and discuss our plans for the future. Our intent is to
regularly inform current and potential investors of our progress as Protectus
Medical Devices becomes uniquely positioned in the medical safety syringe
market.

As you have discovered through our increasing newsflow, Protectus Medical
Devices has developed and patented a revolutionary safety syringe that has the
potential to dramatically reduce needlestick injuries for medical professionals
worldwide.

The Protectus Safety Syringe utilizes a spring-biased sheath that automatically
locks and instantly protects the needle tip if the user loses intentional
control of the device. Our patented design is used in essentially the same
manner as any standard syringe with little special training or in-service
instruction.

Although a prick from a needle may seem innocuous at first glance, the costs of
these needlestick injuries weigh heavily on society, in both monetary and human
terms. Accidental needlestick injuries can lead to the transmission of more than
20 bloodborne diseases, including: AIDS, hepatitis, tuberculosis and other
life-threatening diseases. Despite current safety precautions, there are an
estimated 600,000 to 1 million accidental injuries from conventional syringes
and sharps every year in the United States alone, and these are grossly
under-reported.(1)

Each needlestick costs roughly $3,000 for testing, equating to well over $3
billion spent on administration and follow-up healthcare costs every year.(2)
These numbers exclude the astronomical costs for treatment of diseases actually
contracted through needlestick injuries.

The Protectus Safety Syringe is the only fully automatic, self-sheathing safety
hypodermic syringe that currently meets all U.S. Federal Government and OSHA
mandates designed to protect both healthcare workers and patients alike.

Although there are many competing safety-syringes on the market, all require an
intentional, conscious action by the user to deploy the safety feature, thus
causing many of the same problems as conventional needles, which are soon to be
phased out under Federal Law.

In order to achieve our growth initiatives, Protectus plans to start selling
finished product in the market using contract manufacturing at an FDA-approved
site. Because the Protectus device is the only Safety Syringe that is
automatically self-sheathing, there is a remarkable opportunity for us to
capture significant market share.

From a production standpoint, I am pleased to report that we are nearing the
final stages of signing a contract with a manufacturer for production of the
Protectus Safety Syringe and have narrowed the field to a select few. Based on
preliminary estimates, we anticipate that the Protectus Safety Syringe will be
priced at the low end of the spectrum on the distributor level.

Protectus is not limiting its focus to the US market. In fact, we are also
focused on the global 30 billion-syringe market. We recently received
international patent-pending status in 141 countries for the safety syringe,
giving the Protectus a year and a half of protection as we file individually in
each country of our choosing.

We are also adapting Protectus` innovative technology to a variety of other
medical devices, including a Safety Dental Syringe, a Safety IV Catheter and a
Safety Phlebotomy, or "blood-drawing", device. Protectus has already announced
the patent filing for the Safety Dental Syringe, and looks forward to announcing
the completed filings for additional safety devices in the near future, as well
as significant new features of the dental syringe patent, already filed.

The time for the Protectus Safety Syringe has truly arrived, both as a device
that could potentially revolutionize the healthcare system, and simultaneously
protect countless healthcare workers from needlestick injuries.

On the corporate side of our business, we have chosen consummate experts in
their related fields to enhance our team, which now includes Michael D. Shepard,
who joined our Board of Directors this month. Mr. Shepard will certainly be an
asset to Protectus, with over 30 years of executive level experience, including
his role as CEO of a company that developed and patented the first mobile IV
system.

I thank you for your attention and support. For further and constantly updated
information, please visit our website at www.protectusmedical.com. For access to
our latest Investor Fact Sheet, as well as overview videos and industry
information, please navigate to www.trilogy-capital.com/autoir/ptmd_autoir.htm.

I look forward to communicating with you again soon.

Sincerely,

Dr. John Salstrom
President and CEO
Protectus Medical Devices, Inc.

(1) "Needle-Free Drug Injection and Safety Syringes," 2008, Kalorama
Information.
(2) Ibid.

About Protectus Medical Devices, Inc. (formerly, E-18 Corp.)

Protectus Medical Devices, Inc. (PTMD, formerly, E-18 Corp.), through its wholly
owned subsidiary, SquareOne Medical, Inc., develops and markets innovative
safety medical percutaneous devices that, collectively, have the potential to
dramatically reduce needlestick injuries for medical professionals worldwide. In
the nearly $5 billion global hypodermic syringe market, the Protectus Safety
Syringe, the Company's lead product, is the only fully automatic, self-sheathing
hypodermic safety syringe that currently meets the functional definition of
"Self-Sheathing" mandated by the U.S. Federal Government. None of the
manufacturers of other devices on the market can make this claim. Protectus
Medical Devices has successfully patented its automatic, self-sheathing
hypodermic safety syringe product, and, based on the results of full comparison
clinical trials, the Protectus Safety Syringe (formerly the SquareOne Safety
Syringe) has received the required 510(k) permission from the U.S. FDA to
manufacture and market the device in the U.S. More information about the Company
may be found at www.protectusmedical.com.

Forward-Looking Statements

Under The Private Securities Litigation Reform Act of 1995: The statements in
the press release that relate to the Company's expectations with regard to the
future impact on the Company's results from new products in development are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements are subject to risks and
uncertainties. Words such as "expects," "intends," "plans," "may," "could,"
"should," "anticipates," "likely," "believes" and words of similar import also
identify forward-looking statements. Forward-looking statements are based on
current facts and analyses and other information that are based on forecasts of
future results, estimates of amounts not yet determined and assumptions of
management. Readers are urged not to place undue reliance on the forward-looking
statements, which speak only as of the date of this release. We assume no
obligation to update any forward-looking statements in order to reflect any
event or circumstance that may arise after the date of this release. Additional
information on risks and other factors that may affect the business and
financial results of Protectus Medical Devices, Inc. (formerly, E-18 Corp.) can
be found in the filings of Protectus Medical Devices, Inc. with the U.S.
Securities and Exchange Commission.

Company Contact:
Protectus Medical Devices, Inc.
John Salstrom, President and CEO
1-800-778-8438
moreinfo@protectusmedical.com
or
Financial Communications Contact:
Trilogy Capital Partners
Darren Minton, Vice President
Toll-free: 800-592-6067
info@trilogy-capital.com

Copyright Business Wire 2009